The effect of delaying initiation with umeclidinium/vilanterol in patients with COPD: an observational administrative claims database analysis using marginal structural models

Abstract Background Chronic obstructive pulmonary disease (COPD) is associated with high clinical and economic burden. Optimal pharmacological therapy for COPD aims to reduce symptoms and the frequency and severity of exacerbations. Umeclidinium/vilanterol (UMEC/VI) is an approved combination therap...

Full description

Bibliographic Details
Main Authors: Ami R. Buikema, Lee Brekke, Amy Anderson, Eleena Koep, Damon Van Voorhis, Lucie Sharpsten, Beth Hahn, Riju Ray, Richard H. Stanford
Format: Article
Language:English
Published: PAGEPress Publications 2018-10-01
Series:Multidisciplinary Respiratory Medicine
Subjects:
Online Access:http://link.springer.com/article/10.1186/s40248-018-0151-6